Podcasts about Ras

Have you ever used the "Ostrich Approach" to a difficult relationship, hid from a hard conversation, and ended up winning 50 different imaginary arguments inside your own head?Welcome back to The Catholic Coaching Podcast! In Episode 301, Matt and Erin are diving deeper into our conflict resolution series. Last week, we introduced the PACE framework (Pause, Assume Goodwill, Clarify, Engage). But the big question is: What actually happens inside that very first step—the Pause? Sometimes we abuse the pause to stew in resentment, or we skip it entirely and react out of unregulated emotion. To fix this, we are introducing a powerful new tool in this episode: The FACE Framework.When anger shows up, it's easy to give it a bad rap. But drawing from St. Thomas Aquinas and Catechism #1767, we unpack how anger is actually a morally neutral, complex passion made of two hidden components: Sorrow and Hope.To process your anger cleanly before reason kicks in, you have to FACE it:F – Find the Sorrow: What is the good thing you love that you perceive is being threatened or harmed?A – Assess the Story: Is your narrative a court-of-law fact, or are you editorializing?C – Challenge the Narrative: What fruits are you getting from this story, and how could the opposite be true?E – Examine the Hope: What do you want your anger to actually accomplish? (Restoring justice vs. seeking punishment).We walk through a highly relatable "Odd Couple" college roommate scenario featuring Brian (a highly ordered Melancholic) and Andy (a carefree Sanguine) to show RAs, ministry leaders, and coaches exactly how to accompany someone through a heated moment without falling into "story fondling."Whether you're dealing with a difficult coworker, a spouse, or navigating campus ministry, learning to purify your anger will completely transform your relationships.Send us Fan MailSupport the show____________________► Make sure to SUBSCRIBE to the Metanoia Catholic YouTube Channel!► Discover How God Is Speaking to You In Prayer► Find out your temperament: Take the Free Quiz► Get the Conversation Starter Guide (FREE) ► Take the Quiz: WHAT TYPE OF COACH ARE YOU?► GET THE DAILY SEVEN JOURNAL!This interactive journal will help you transform your life from the inside out by teaching you how to grow in gratitude, set healthy goals, and gain mastery over your thoughts.► JOIN THE ACADEMY!Your online resource of classes, tools, and community to ramp up your growth and really change your life. Learn from the Metanoia Catholic coaches in webinars, live coaching calls, Lectio Divina, and more with your monthly membership.____________________► SUB...

Why do high-performing men lose their identity in midlife? After 35 years on the front lines of emergency medicine and over 170,000 patients treated, Dr. Kenneth Ro stepped back and named something he was seeing repeatedly. The men coming through his ER weren't just breaking down physically. They were losing their identity, their edge, and their sense of purpose. In this conversation, Larry Olsen sits down with Dr. Ro to talk about what happens when a man's identity gets fused to his profession, and what to do about it before it costs him his health, his relationships, or his career. What you'll hear: • The Triple Caretaker Effect and why most men get the order wrong • Why "midlife crisis" is the wrong frame and what Dr. Ro calls a midlife inflection point • The Stephen Covey line that most leaders have heard but very few apply: climbing the ladder against the wrong wall • Dr. Ro on why silence is a bigger health risk factor than blood pressure or cholesterol • What happens when I've attached who I am to what I do? ABOUT DR. KENNETH RO Dr. Kenneth Ro is a double board certified emergency physician with 35+ years on the front lines of emergency medicine and over 170,000 patients treated. He is the author of Prime: How to Win the Second Half of Life and the founder of the Reclaim Method, a framework helping high-performing men in midlife rebuild their health, clarity, and confidence. Dr. Ro practices in Cypress, Texas. ABOUT LARRY OLSEN Larry Olsen is a Two-Time Vistage Speaker of the Year and Fortune 50/500 Executive Performance Advisor with 40+ years of client work at Toyota, PepsiCo, Starbucks, Harley-Davidson, Honda, American Airlines, State Farm, Frito Lay, Lexus, and Tropicana. He is the author of Get a Vision and Live It! and the founder of Performance Driven Neurology. IF THIS LANDED FOR YOU The next step is Larry's Brain Hacks Intensive. It is a guided practice that walks you through the foundational mindset shifts Larry teaches Fortune 500 executives. Brain Hacks Intensive: https://neuromindedcollective.com/brain-hacks-challenge CONNECT WITH LARRY Website: larryolsen.com LinkedIn: linkedin.com/in/larry-r-olsen CONNECT WITH DR. KENNETH RO Website: kennethromd.com Book: Prime: How to Win the Second Half of Life (Amazon, search Ken Ro MD) SUBSCRIBE FOR MORE New episodes of the Brain Vault Podcast publish every other Wednesday. Yours in growth, Larry

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm, al-ḥamdu lillāhi rabbil-‘ālamīn, wa-salātu was-salām ‘ala ash-sharafi al-anbiyā’ wal-mursalīn, Muḥammadur Rasūlullāh sallallāhu ‘alayhi wa ‘alā ālihi wa sahbihi wa-sallam, taslīman kathīran kathīran. Amma ba’du, my brothers and sisters, Allāh subḥānahu wa ta’ālā is the One who controls everything, wa huwa ‘alā kulli shay’in qadīr. Allāh subḥānahu wa ta’ālā is Qadīr… Continue reading Be pleased with Allahﷻ’s decree

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm, wa raḥmatullāhi rabbil ‘alameen, wa salātu wa salāmu ‘ala ashrafil anbiyā’ wal mursaleen, Muḥammadun Rasūlullāh sallallāhu ‘alayhi wa ‘ala ālihi wa sahhayhi, tasliman kathīran kathīran. My brothers and sisters, a young man came to Rasūlullāh sallallāhu ‘alayhi wa sallam, and he said to him, “Ya Rasūlullāh sallallāhu ‘alayhi wa sallam,… Continue reading Small but powerful dua

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Alhamdulillāhi Rabbil ‘Alāmīn. Wa salātu wa salāmu ‘alā sharifin anbiyā’ wal mursalīn, Muḥammadun Rasūlullāh sallallāhu ‘alayhi wa ‘alā ālihi wa sahbihī wa sallam. Tasleeman kathīran kathīra. Fama ba’du. My brothers and sisters, we have been talking about since yesterday regarding the issue of what happens when Allāh protects us and… Continue reading Don’t despair of the mercy of Allahﷻ – Part 2

On this week's episode, Graig Suvannavejh, Eric Schmidt, Paul Matteis and Financial Times' Oliver Barnes kicked off with the biotech market, with the XBI in positive territory and 12 biotech IPOs completed so far this year. They expected the IPO window to remain open for high-quality private companies. The group also overviewed recent financings, including SonoThera's $125 million Series B, City Therapeutics' $100 million Series B, Ethyreal's $101 million Series A, and Summit's decision to cancel a $500 million secondary offering. In data news, the co-hosts covered Tango's combination data with Revolution Medicines' RAS inhibitor. They also discussed Incyte's acquisition of Vega Therapeutics as a pipeline-building move ahead of Jakafi's 2028 patent expiration and J&J's acquisition of Firefly, with the RAS inhibitor space expected to remain hot. The group also discussed GSK's acquisition of Nuvalent -- its largest deal to date -- for two late-stage lung cancer assets. Oliver added perspective on biotech deal leaks, following the Incyte/Vega deal and GSK/Nuvalent deals this week. In partnership updates, Novartis expanded its molecular glue work with Orionis, Lilly licensed an Alzheimer's candidate from AlzeCure, and Corvus supported China partner Angel Pharmaceuticals. The episode concluded with the latest in rare disease and gene therapy, covering Novartis' FSHD program, FDA flexibility, Rett syndrome programs, and Sensorion's exit from hearing loss development. *This episode aired on June 12, 2026. 

We're dropping this bonus episode because something genuinely historic happened in oncology and we couldn't wait until our regular schedule to talk about it. Dr. Mark Lewis, GI medical oncologist, pancreatic cancer survivor, and one of our absolute favorite guests. He just got back from ASCO, the Super Bowl of oncology, where a new drug called daraxonrasib received one of only about six standing ovations in the conference's history, including applause that broke out mid-sentence when researchers showed the survival data on-screen. The drug targets a mutation that drives the vast majority of pancreatic cancer and has been considered "undruggable" for decades and it works not by attacking the mutation directly, but by cutting off the downstream signals it sends, like snipping the wire instead of fighting with the switch. The results are remarkable. In patients who had already received standard chemotherapy, daraxonrasib roughly doubled survival time and delivered it in pill form rather than an IV every two weeks, a meaningful quality-of-life difference for people who are already facing the hardest year of their lives. Mark walks us through the science, the side effects (rash, because RAS proteins live in skin too), the path to FDA approval, and what this means beyond pancreatic cancer, the same KRAS mutations show up in about 30% of lung cancers and 40% of colon cancers. Takeaways: Pancreatic cancer has been devastatingly hard to treat, 85% of patients are incurable at diagnosis because it spreads silently and there's no good screening, leaving most patients with a median survival of about a year on IV chemotherapy. KRAS, the mutation driving nearly all pancreatic cancer, was long considered "undruggable", the protein was so smooth and spherical that no drug could bind to it, and researchers were actively discouraged from pursuing it as a target. Daraxonrasib works by cutting the power rather than fighting the switch, instead of binding to the KRAS protein itself, it uses molecular glue to interrupt the downstream growth signals the mutation sends, an approach that took decades to develop and wasn't taken seriously until now. The trial results roughly doubled survival and the treatment is a daily pill, not an IV, patients who had already been treated with chemotherapy gained approximately an additional year of life with improved quality of life, which represents one of the most significant advances in pancreatic cancer treatment in decades. This breakthrough has implications far beyond the pancreas, KRAS mutations drive about 30% of lung cancers and 40% of colon cancers too, and proving the target is druggable opens the door to a new generation of treatments across multiple cancer types. Want more Dr. Mark Lewis? X: @marklewismd To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://glaucomflecken.com/glauc-to-me/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you are interested in buying a book from one of our guests, check them all out here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/dr.glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anatomywarehouse.com/?aff=14⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm, al-ḥamdu lillāhi rabbil-‘alāmīn, wa salātu wa salāmu ‘ala ash-sharafi al-anbiyā’ wal-mursalīn, Muḥammadur Rasūlullāh sallallāhu ‘alayhi wa ‘ala ālihi wa sahbihi sallam, tasleemun kaseerun kaseerun. Amma ba’du, my brothers and sisters, I want to remind myself anew. Sometimes, our life is going on smoothly, alhamdulillah, we are doing what we should… Continue reading Don’t despair from the mercy of Allahﷻ

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.   We discussed: The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients. The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib. The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors. Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice. The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment! #PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Al-ḥamdu lillāhi Rabbil-‘Ālamīn, wa salātu wa salāmu ‘alā ashrafil-anbiyā’ wal-mursalīn Muḥammadur-Rasūlullāh ﷺ. Tasliman kathīran kathīra. Fammabadu? My brothers and sisters, I am sitting in my hotel room in Cochin. And this is my view, and it’s a lovely view. The water is part of the backwaters from Cochin Harbour. And… Continue reading Don’t be like the fish

I don't know about you but after last week's topics I really needed some fun and joyful content so this week for Mood for News we are covering only POSITIVE popculture news stories from the last couple of weeks. We start with the latest deets from Dua Lipa and Callum Turner's wedding festivities in Palermo, Sicily. Then we talk about New Zealander Tim Payne being classed the 'main character' for the 2026 FIFA World Cup. I fangirl about Hudson William's iconic acceptance speech at the Canadian Screen Awards. Noah Cyrus and Frankie Jonas got the cutest matching Ponyo tattoos ever and I reveal why I haven't really watched Studio Ghibli so far and lastly Mattell is releasing full length Barbie movies on YouTube, this is not a drill!!Tell me what childhood film traumatised you and most importantly - let me know what you think!Instagram - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@moodforfeud⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@moodforfeud ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Support the show on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Ko-fi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ all funds go towards upgrading my podcast gear!⁠⁠Also, for those interested the tea I mention is Twinings New York Breakfast - Caramel flavoured black tea.Timestamps00:00 Intro03:15 Dua Lipa and Callum Turner tie the knot12:14 Tim Payne is FIFA main character18:56 Hudson Williams acceptance speech22:15 Noah Cyrus and Frankie Jonas matching tattoo25:25 Barbie movies are on YouTube28:16 Personal faves Intro/Outro MusicYarWritten by Ryan SkeltonProduced by Ras & Sakunera#DuaLipa #CallumTurner #DuaLipaWedding #DuaLipaCallumTurner #SicilianWedding #PalermoWedding #DuaLipaBride #DuaLipaBottegaVeneta #DuaLipaMarried #CharliXCXWedding #TroySivan #JoeAlwyn #EltonJohn #DuaLipa2026 #CelebWedding2026 #MarkRonson #DonatellaVersace#HudsonWilliams #HeatedRivalry #CanadianScreenAwards #HeatedRivalryCSA #ShaneHollander #ConnorStorrie #IlyaRozanov #GayHockeyRomance #HeatedRivalrySeason2 #CanadianScreenAwards2026 #HeatedRivalryRecord #GayBottomEyes #BestDramaSeries #CraveOriginal#TimPayne #NoPayneNoGain #FIFAWorldCup2026 #AllWhites #NewZealand #WorldCup2026 #TimPayneViral #ElScarso #ValenScarsini #WellingtonPhoenix #WorldCupMainCharacter #TimPayneInstagram #NewZealandFootball #WorldCup2026Viral #UnderdogWorldCup #FIFA2026#NoahCyrus #FrankieJonas #PonyoTattoo #NoahCyrusFrankieJonas #FrankieJonasNoahCyrus #StudioGhibli #Ponyo #MatchingTattoos #JonasBrothers #MileyCyrus #DisneyKids #PonyoLovesSosuke #CelebTattoo #DisneyChannel #NoahCyrusCrush#PopCulturePodcast #TrendingTopics #CelebDrama #PopCulture2026 #EntertainmentNews #WeeklyRecap #HotTakes #Podcast2026 #ViralMoments2026 #WhatEveryoneIsTalkingAbout

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm, al-ḥamdu lillāhi rabbil-‘alāmīn, wa salātu wa salāmu ‘ala ashrafil-anbiyā’ wal-mursalīn, Muḥammadur Rasūlullāh ṣallallahu ‘alayhi wa sallam, tasliman kathīran kathīrā. Umar Badu, my brothers and sisters, we are looking at the rules of success. These are things that Allah subḥānahu wa ta’ālā sent us into this world to be successful, and… Continue reading Beat fear of failure

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of data from the phase 3 RASolute 302 trial (NCT06625320), a landmark study presented at the 2026 ASCO Annual Meeting that has established daraxonrasib (RMC-6236) as the new standard of care (SOC) for the second-line treatment of patients with metastatic pancreatic adenocarcinoma.The discussion began by highlighting the historical context of second-line treatment, where standard chemotherapy options like FOLFOX (leucovorin calcium, fluorouracil, and oxaliplatin) or gemcitabine-based regimens typically yielded a median overall survival (OS) of only approximately 6 to 7 months. Although RAS mutations drive approximately 90% of pancreatic cancers, they were historically considered undruggable. Daraxonrasib addresses this challenge with its mechanism of action of an oral, RAS(ON), multi-selective, tri-complex inhibitor that targets the active GTP-bound state of both mutant and wild-type RAS, covering variants at codons G12, G13, and Q61.The RASolute 302 trial was an international, open-label study that randomly assigned patients with progression after 1 prior line of therapy to receive either daaxonrasib or investigator's choice of chemotherapy. In the RAS G12–mutated subpopulation of patients, daraxonrasib generated a higher median OS compared with chemotherapy. Similar benefits were observed with daraxonrasib in the overall population, where the median progression-free survival nearly doubled.Drs Armstrong and Tawagi emphasized that the toxicities associated with daraxonrasib are highly clinically relevant and distinct from the myelosuppression seen with chemotherapy. Key adverse effects (AEs) include dermatologic events, diarrhea, and stomatitis. Management of these AEs is critical; the hosts recommended the use of prophylactic oral antibiotics and topical corticosteroids to manage rash, alongside standard oral care for mucositis. Despite being associated with these AEs, daraxonrasib was better tolerated than chemotherapy, with a low treatment discontinuation rate due to AEs.Daraxonrasib is currently accessible in the US through an Expanded Access Program and is undergoing accelerated review for full FDA approval. The experts noted that the agent is being further investigated in the frontline setting through the phase 3 RASolute 303 trial (NCT07491445) and in the adjuvant setting via the phase 3 RASolute-304 trial (NCT07252232), potentially expanding the agent's effect across the continuum of pancreatic cancer care.

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Alhamdulillāhi Rabbil ‘Ālamīn. Salātu wa-s-salām ‘ala ashrafil anbiyā’ wal mursalīn, Muḥammadir Rasūlallāh sallallāhu ‘alayhi wa ‘alā ālihi wa sahbihī, sal-lam ‘alā alayhi wa sallam, tasliman kathīran kathīran. Amma ba’du. Yesterday we spoke about the four things that are necessary for success. I didn’t mention all four yesterday, but today I… Continue reading Focus – Consistent effort – for a decade

2026 年 5 月底，一项名为 RESolute 302 的三期临床试验结果登上了 ASCO 压轴场。10 多年来，胰腺癌的中位总生存期，都卡在 6 个月出头，而一款叫做 Daraxonrasib 的新药，把这个数字拉到了 13.2 个月——死亡风险下降了 60%。为什么这件事如此震撼？因为它攻克的靶点叫做 KRAS——一个 1982 年就已被发现、与三成人类癌症相关、在胰腺癌中突变率接近 95%，却被整个科学界宣判了近 40 年"不可成药"的基因。这期节目里，我们聊了聊 RAS 蛋白到底是什么，它为什么那么难成药；第一代 KRAS 药物是为什么对胰腺癌几乎无效；以及 Daraxonrasib 是怎样突破“不可成药”的极限的。时间轴[00:13] Daraxonrasib 将胰腺癌的中位生存期延长了一倍[02:30] RAS 靶点：癌症研究的珠穆朗玛峰[03:59] RAS 基...去小宇宙查看完整单集简介在小宇宙查看该单集文稿

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of buzzy data drops, practice-changing posters and insightful sessions. In this week’s episode of "The Top Line," Fierce Biotech and Fierce Pharma’s Darren Incorvaia, Zoey Becker and Angus Liu break down the biggest takeaways from their weekend of reporting live from the Windy City. From “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset, ASCO 2026 reflected new and continuing trends within the evolving state of cancer care today. To learn more about the topics in this episode: ASCO: Revolution Medicines confident in RAS leadership as rivals square up ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary See omnystudio.com/listener for privacy information.

What does it actually mean to "tune into the frequency of abundance"? In this episode, Ava unpacks one of the most repeated phrases in manifesting culture and grounds it in nervous system science and practical strategy. Drawing on 15+ years of personal practice, she breaks down the two real pillars of manifesting money: the yin of embodied visioning and nervous system calibration, and the yang of aligned, exploratory action. If money feels charged, overwhelming, or just out of reach, this episode offers a grounded, functional framework for understanding why, and what to actually do about it. Chapter Markers 00:00 Welcome + episode intro 01:00 Revisiting the four-part manifesting series 03:00 Why surface culture makes our efforts less effective 05:00 Why money and manifesting are so intertwined 06:00 Ava's personal history with manifestation practice 08:00 What does "tuning into the frequency of abundance" actually mean? 11:00 The yin and yang of manifesting money 13:00 Why money is nervous-system charged: shame, scarcity, family scripts 15:00 Journaling, visioning, and embodied dreaming as practice 17:00 Aligned action: why strategy is part of manifestation 20:00 The reticular activating system (RAS) explained Increasing accessibility to functional healing + non-dual spiritual oneness: www.functionalspirituality.com   Free resources: Newsletter sign-up:  A monthly update for me on new offers and the energy of the month. Free training - 3 part method of Functional Spirituality: Learn the clear, practical framework for deep healing, emotional regulation, and spiritual integration.   Connect on Socials Where you can hear from us in daily life Personal account & Functional Spirituality: @functionalspirituality  Studio: @spandaschool  Lavandula Botanicals: @lavandula.botanicals

Your brain is constantly filtering what you notice - and that filter might be sabotaging your relationship. Julie and David Bulitt explore the Reticular Activating System (RAS), a neuroscience concept that explains why you might only see the negative in your partner when you're disconnected, how it blinds you to red flags when you're newly in love, and most importantly, how to retrain your brain to notice the positive. They discuss the 5:1 ratio, the danger of affairs and disconnection, and practical tools like gratitude journaling and assuming good intentions to shift your RAS into positive territory. If you've ever wondered why your perception of your partner can change so dramatically, this episode has the answers.Learn more at thebulitts.comSubscribe on YouTube: @TheBulittsJulie is not your therapist and David is not your lawyer. This podcast is meant for educational and entertainment purposes only.

Door decorations and bulletin boards are more than check-the-box tasks; they are often the first impression residents have of their community. In this episode of Roompact's RA*Chat,, we sit down with a Nikki Garcia to explore how RAs can create intentional, engaging, and meaningful visuals that go beyond aesthetics. From planning timelines to interactive strategies,...... Continue Reading →

What if the only real limit is the story your brain keeps accepting? Kyle and Brent Pease — co-founders of the Kyle Pease Foundation and veteran Ironman competitors — have completed over 150 races together, including multiple Ironman events, with Kyle racing from his wheelchair. But this isn't a story about disability. It's about what becomes available when you decide to see possibility where others see a ceiling. In this episode, Kyle and Brent share how a single question — can people in wheelchairs do an Ironman? — launched a movement that helped over 170 athletes cross more than 1,300 finish lines in one year alone. If you want to lead at a higher level, perform with more grit, and discover what you're actually capable of, this conversation will rewire the way you see your own limits.   ABOUT LARRY OLSEN Larry Olsen is a Two-Time Vistage Speaker of the Year and Fortune 50/500 Executive Performance Advisor with 40+ years of client work at Toyota, PepsiCo, Starbucks, Harley-Davidson, Honda, American Airlines, State Farm, Frito Lay, Lexus, and Tropicana. He is the author of Get a Vision and Live It! and the founder of Performance Driven Neurology, the methodology combining cognitive psychology and neuroscience for C-suite leadership.   ABOUT KYLE AND BRENT PEASE Kyle and Brent Pease are brothers, co-founders of the Kyle Pease Foundation, and one of the most decorated inclusive endurance duos in the world. Kyle, who has cerebral palsy and has used a wheelchair for 41 years, is an Ironman finisher and the face of a 15-year movement that is redefining what inclusion looks like in endurance sports. Learn more about the Kyle Pease Foundation at kylepeasefoundation.org.   READY TO START YOUR OWN BRAIN HACKS PRACTICE? If something Kyle, Brent, or Larry said landed for you in this episode, the next step is the Brain Hacks Intensive. It is a guided practice that walks you through the foundational mindset shifts behind the Performance Driven Neurology methodology, the same shifts Larry teaches Fortune 500 executives and the same principles Kyle and Brent have lived out for 15 years. Brain Hacks Intensive: https://neuromindedcollective.com/brain-hacks-challenge   CONNECT WITH LARRY Website: larryolsen.com LinkedIn: linkedin.com/in/larry-r-olsen CONNECT WITH KYLE AND BRENT Website: kylepeasefoundation.org

On this episode of The Ty Brady Way, Ty sits down with George Blackwell Smith, the founder of Lucky Cajun Seasoning. George grew up in Chattanooga, Tennessee, moved to Baton Rouge for high school, and fell in love with the food. Not just the taste of it, but the way it made him feel. That curiosity led him to culinary school, years in restaurant kitchens, and eventually to building a seasoning brand from scratch out of his home during COVID. George is the kind of builder who figures things out the hard way and is honest about it. He talks about the early days of navigating Tennessee cottage food laws just to get his first blend to market, spending a year trying to find a licensed kitchen he could actually afford, and learning quickly that chasing shelf space in big box stores was a lot of footwork for very little return. He made the call early to go direct to consumer and build the relationship with the customer himself. That decision has shaped everything since. You will hear him get real about the failure that changed him most. He had to close a restaurant and file for bankruptcy. He says when it finally ended, something unexpected happened. His head got clear. All the things he should have done differently came rushing in at once, and for the first time in a long time he could actually think straight. He took that clarity with him and has been building differently ever since. George also talks about what it means to create your own luck. He is not talking about wishful thinking. He is talking about the RAS, the part of your brain that only finds what it is already looking for. If you are not actively looking for opportunity, you will not see it even when it is right in front of you. He used that exact principle the day of this recording to find a new sales channel he had been overlooking for months. And if you are trying to change your luck this week, he gives you three things to start with. Read self-improvement books. Build a simple morning routine. And make a short list of what actually needs to get done today, then go do it. This one is grounded, practical, and worth your time.

Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/03-06-2026Nesta quarta-feira, o boletim aborda um marco histórico na oncologia de precisão, alertas fundamentais de farmacovigilância e uma das maiores crises de saúde pública pediátrica. Analisamos os resultados emocionantes do daraxonrasib apresentados na ASCO, uma pílula oral que dobrou a sobrevida global no cancro de pâncreas metastático ao atuar sobre mutações RAS. Detalhamos a resolução da Anvisa que suspendeu lotes de medicamentos essenciais, como Halaven e enalapril, por desvios de qualidade. Por fim, trazemos no Radar o Dia de Conscientização Contra a Obesidade Mórbida Infantil, reforçando a importância do rastreio precoce e da abordagem familiar. Afya News. Informação médica confiável e atualizada no seu tempo.

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Al-ḥamdu lillāhi Rabbil-‘Ālamīn, wa salātu wa salāmu ‘alā ashrafil-‘ibād wal-mursalīn Muḥammadur-Rasūlallāh ﷺ. Tasliman kathīran kathīran. My brothers and sisters, Allāh subḥānahu wa ta’ālā mentioned the story of Mūsā alayhis-salām in 28 out of the 30 juz of the Qur’an, so it is everywhere but very beautifully and very concisely. Allāh… Continue reading Iyyaka Na’abudu

Description:  How do GLP-1 receptor agonists or GIP agonists work and what is the impact for my psoriatic disease? Hear dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber answer such questions and more.           Join host Archie Franklin as he takes a deep dive into the use of GLP-1 receptor agonists and GIP agonists and the convergence of systemic inflammation related to psoriatic disease with renowned dermatologist and Vice Chair of the NPF Medical Board, Dr. Ronald Prussick from Washington Dermatology Center in Rockville and Frederick, MD, and, cardio-immunologist Dr. Brittany Weber, Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. Learn more about the use of incretin hormones, the impact of weight management on psoriatic disease, metabolic and cardiovascular risk, as well as results from the TOGETHER-Pso and TOGETHER-PsA clinical trials.  This episode addresses the actions of incretin hormones (GLP-1 receptor agonist and GIP agonist) and how such use may be beneficial in the management of inflammation related to psoriasis and psoriatic arthritis.  Thank you to Lilly for their support of this program activity.  Timestamps: (0:00)  Intro to Psoriasis Uncovered & guest welcome dermatologist Dr. Ronald Prussick and cardio-immunologist Dr. Brittany Weber.  (1:35)  What are incretin hormones and how GLP-1 or GIP receptor agonists (RA) inhibit appetite to initiate weight loss. (3:29)  Why GLP-1 RAs are of interest in the management of psoriasis and psoriatic arthritis. (5:23)  The metabolic, cardiovascular, and psoriatic disease convergence. (7:19)  Will reduction of inflammation impact cardiovascular risk? (10:59) Treatment challenges associated with having psoriatic disease and being overweight or obese. (13:45)  Key points around the use of GLP-1 receptor agonists when managing psoriasis and psoriatic arthritis. (17:06)  Results of the TOGETHER-PsO and TOGETHER-PsA phase 3 clinical trials combining use of an IL-17 inhibitor and a GIP and GLP-1                receptor agonist therapy. (19:07)  Having the conversation of adding a GLP-1 RA medication to a treatment regimen. (22:40)  The paradigm shift of GLP-1 receptor agonists and the impact they can have on shared inflammatory pathways. Key Takeaways: ·       Glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists are two incretin hormones that assist in managing excess body weight -- which as a result can be helpful in managing inflammation in the body.   ·       Psoriasis isn't just a skin and joint disease. It's a complex network of systemic inflammation with shared inflammatory pathways that worsens with increased weight impacting the severity of the disease, and accelerates the risk of metabolic dysfunction, and cardiovascular disease.   ·       The best outcomes occur as a result of multidisciplinary collaboration to address the impact of excess weight and systemic inflammation. If you are struggling to lose weight with diet and exercise, speak with your medical team about your options including the use of GLP-1 or GIP agonists.   Guest Bios: Renowned dermatologist Ronald Prussick, M.D., Medical Director of the Washington Dermatology Center in Rockville and Fredrick, Maryland, specializes in the treatment of psoriasis along with other diseases of the skin, hair, and nails. Dr. Prussick is also a Clinical Associate Professor in Dermatology at George Washington University in Washington, D.C.. Dr. Prussick has a research interest in the impact of diet on psoriatic disease and metabolic health, first becoming interested after being involved in Dr. Joel Gelfand and Dr. Nehal Mehta's work in vascular inflammation trials using FDG-PET/CT scans to view systemic and cardiovascular inflammation associated with psoriatic disease. Dr. Prussick has since participated in the development of the 2018 Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis and more recently the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Dr. Prussick is Vice Chair of the NPF Medical Board which provides clinical direction, treatment guidance, and education oversight to the organization and its Executive leaders.  Brittany Weber, M.D., Ph.D. is a cardio-immunologist who is the Director of the Cardio-Rheumatology/ Cardio-Dermatology Program at the University of Texas Southwestern. She is also a member of the Division of Cardiology, a clinical investigator, and imaging specialist. Dr. Weber's research integrates advanced imaging, molecular biology, clinical trials, and population health to understand how systemic inflammation and immune deregulation drives cardiovascular dysfunction. Prior to joining UT Southwestern in 2025, Dr. Weber served on the faculty at Harvard Medical School and was the Director of the Cardio-Rheumatology Clinic at Brigham and Women's Hospital, a nationally recognized clinic addressing inflammation-related heart disease through collaborative, patient centered care. Dr. Weber is also an author on the position statement "GLP-1 Receptor Agonists in Psoriasis: A Primer from the National Psoriasis Foundation Medical Board". Resources: "The Metabolic Collison and How You Can Take Control with Psoriatic Disease" podcast episode with dermatologist Dr. Ronald Prussick and registered dietitian Danielle Cahalan   "NPF Medical Board Issues GLP-1 Primer for Dermatologists" Press Release "Finding My Path to Managing Psoriatic Disease and Excess Weight" podcast episode featuring dermatologist Dr. Erin Boh, patient advocate Brian Lehrschal, and moderator Jennifer Bomberger. 

Dr. Monty Pal shares highlights from the final day of ASCO26, including new research on treating anemia in myelofibrosis, advances in RAS-mutated mCRC, novel therapies for AML, and a potentially practice-changing trial in TNBC. LINK TO FULL TRANSCRIPT

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively. Topics Covered: Overview of the RASolute-302 study Impact of Daraxonrasib on overall survival RAS mutations in pancreatic cancer Mechanism of action of RAS inhibitors Side effects and management strategies Tune in now for an enlightening discussion on the future of pancreatic cancer treatment! #ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm, Alhamdulillāhi Rabbil ‘Alāmīn, Wa salātu wa salāmu ‘alā ashrafil anbiyā’ wal mursalīn, Muḥammadur Rasūlullāh ṣallallahu ‘alayhi wa sallam, Tasliman kathīr, Fahm ābādun. The question is: first of all, is music haram or not? Second, if it is haram, then seeing it used in content creation, advertising, and different contexts by… Continue reading Q and A – #1

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Al-ḥamdu lillāhi Rabbil-‘alāmīn. Wa salātu wa salāmu ‘ala ash-sharafi al-anbiyā’ wal-mursalīn, Muḥammadur Rasūlallāh ṣallallāhu ‘alayhi wa ‘alā ‘ālīhi wa saḥbihī wa sallam. Tasliman kathīran kathīrān. Umar Badu, my brothers and sisters, we ask Allāh subḥānahu wa ta’ālā to give us khatima bil-khayr. Because Rasūlullāh ṣallallāhu ‘alayhi wa sallam said, innama… Continue reading Prepare for death

“Ey iman edenler! Kendinizi ve ailenizi, yakıtı insanlar ve taşlar olan ateşten koruyun.O ateşin başında gayet katı, çetin, Allah'ın kendilerine verdiği emirlere karşı gelmeyen ve kendilerineemredilen şeyi yapan melekler vardır.” Tahrim 6“Ey inkâr edenler! Bu gün özür dilemeyin! Siz ancak yapmakta olduklarınızın karşılığını görüyorsunuz.” 7Dünyadaki ateşler taşı yakamaz. Cehennem ateşi nasıl bir ateş ki yakıtı insan ve taş?“Keşşâfda, bu ifadeye, "Günahları terkedip, taatları yapmak ve ailenizi, kendinizi sorumlu tuttuğunuzşeylerle sorumlu tutmanız suretiyle, koruyun" manası verilmiştir. Yine bu ifadeye, "Kendinizi, nefsinizidavet ettiği şeylerden koruyun. Çünkü nefis, size kötü şeyleri emreder" manası verilmiştir."Bu ateşin başında iri gövdeli, sert tabiatlı melekler vardır." Cenâb-ı Hakk bu ifadeyle, on dokuzzebânî (cehennem bekçisi melek) ile onların yardımcılarını kastetmiştir. Bunlar, alabildiğine büyük, haşin vesert meleklerdir. Onların bu şekilde yaratılmış olmaları yadırganacak bir şey değildir. Yahut da onlar, Allah'ındüşmanlarına karşı, alabildiğine şiddetli, Allah dostlarına karşı alabildiğine merhametli oldukları için,hilkatlerinde değil de işlerinde böyle serttirler. Nitekim Hak teâlâ (mü'minleri vasfederken), "(Onlar),kâfirlere karşı alabildiğine sert; birbirlerine karşı ise son derece merhametlidirler" (Fetih 29) buyurmuştur.Ayetteki, "Ne emrolundular ise onu yaparlar" ifadesi. işin gerektirdiği ortamdan ötürü onların, çok çetin vesert olduklarına delâlet eder. Çünkü onlar Allah'ın emirlerini yerine getirme ve düşmanlarından intikamalma hususunda asla şefkatli davranmazlar. Burada, meleklerin, âhirette, Allahü teâlâ'nın emir ve yasaklarıile mükellef olmaya devam ettiklerine bir işaret vardır. Çünkü onlardan sâdır olacak isyan. Allah'ın emir veyasağına muhalefet olur."Ey kâfirler, bugün özür dilemeyin" buyurmuştur ki bu, "Onlara, "Bugün mazeret beyan etmeyin" denilecek"takdirindedir. Çünkü mazeret beyan atmek, tevbe etmek demektir. Tevbe ise, cehenneme girdikten sonra,artık makbul değildir. Binâenaleyh mazeret beyan etmek, onlara bir fayda vermez. yani, "Sizin yapmışolduğunuz o kötü amelleriniz, hikmet-i ilahiyye gereği size bu azabı gerekli kılmıştır."Allahü teâlâ, "Eğer yapamazsanız, ki kesinlikle yapamayacaksınız, o halde yakıtı insanlar ve taşlar olan oateşten korununuz. Zira o, kâfirler için hazırlanmıştır" (Bakara, 24) buyurarak, cehennemin kâfirler içinyaratıldığını bildirmiştir. Öyleyse burada, mü'minlere böyle hitap etmesinin hikmeti nedir? Deriz ki:Fasıkların derekeleri, kâfirlerin derekelerinin üstündedir. Çünkü fasıklar da kâfirlerle birlikte, aynı yerde,yani cehennemdedirler. Bundan dolayı mü'minlere, "Bu ateşin kendileri için hazırlandığı kimselerlebirlikte olmamanız için, fısk-ı fücurdan (günahtan) alabildiğine kaçınmak suretiyle kendinizi bu ateştenkoruyun" denmiştir. Bu hitapla, Cenâb-ı Hakk'ın onlara, mürtedlikten korunmalarını emretmiş olması dauzak bir ihtimal değildir.” RaziAli (radıyallahü anh), Katade ve Mücahid şöyle demişlerdir: Yaptığınız işlerle kendinizi koruyunuz, onlarayapacağınız tavsiyelerle de aile halkınızı koruyunuz.el-Kuşeyrî'nin zikrettiğine göre bu âyet-i kerîme nazil olunca, Ömer (radıyallahü anh) şöyle demiş:Ey Allah'ın Rasûlü! Haydi kendimizi koruduk diyelim. Peki aile halkımıza ne yapabiliriz?' Peygamber şöylebuyurdu: "Allah'ın size yasakladığı şeylerden onları alıkoyarsınız, Allah'ın emrettiklerini onlara daemredersiniz.""Sen aile halkına namazı emret, kendin de sabırla ona devam et" (Taha, 20/132)"Önce yakın akrabanı uyar." (eş-Şuara, 26/214)"Çocuklarınıza yedi yaşında namaz kılmalarını emrediniz. (Kılmazlarsa) on yaşında onları (hafifçe)dövünüz ve yataklarını birbirinden ayırınız." Ebû Dâvûd, I, 133; Hâkim“Hepiniz çobansınız ve hepiniz sürüsünden sorumludur. İnsanların başındaki İmâm (İslâm devletininyöneticisi) bir çobandır ve o, onlardan sorumludur. Adam aile halkı üzerinde bir çobandır ve onlardansorumludur."

In this episode Betsy recounts her trip to Florida and the signs that she experienced while traveling. She explains the ‘put it down’ practice and how it can best serve us in our lives as well as how our brains notice things based on our focuses. This one is a good one if you need a reminder to take stock and choose you. Transcript:  Welcome to The Art of Living Big, where we explore how to live intentionally and with more joy. I’m Betsy Pake, your host, master, coach, and creator of the Navigate Method. Here to help you listen in to your true desires, elevate your standards, and live life to the fullest. Now, let’s go live big. Hi, everybody. Welcome to the show today. I recorded this yesterday, and it was amazing. You missed a really good show. My microphone wasn’t on, and I, if you are new here, I do these podcasts. I come up with an idea, and then I just talk. So the kinda cool thing is this will be a totally different show than yesterday, although the same topic. I s- I’m sticking to the same theme ’cause I do have a story that I wanna tell you, and it may be a story that you heard if you’re on my mail list. But I wanna dive in a little bit deeper, and I wanna give you some tools, as we go through this. I wanna talk a little bit about my, my trip to Florida and something very cool that happened, and I, I’m gonna call it magic. I believe that there’s magic that happens all around us, and I believe you have magic that happens all around you, too. So I’m gonna tell you how to find it and how to use it So I’m gonna tell you how to find it and how to use it so that you can actually make your life easier and, you know, maybe a little bit more fun too. So if you’ve been here for a while, you may know that my whole dang life I’ve wanted to move to the beach, and just a few months ago I got the idea that actually there was nothing stopping me and I could do that. And so this, th- I guess it was last weekend, two weekends ago. Memorial Day was this past weekend. The weekend before, I decided I was gonna go down to Florida and I was gonna look around. You know, if you listen to the episode about how I make big decisions, I really was leaning into California, and in fact, had a trip planned for California for this week that ended up getting rerouted. But I had decided that I was also gonna check out Florida for a lot of different reasons. You know, I grew up on the East Coast. Um, my dad is on the East Coast. He, he … And I’m h- I, I was about to say he’s elderly. I guess he is. He’s 85. I guess, I guess that is elderly. It just feels weird to call him that, but he is. He’s not sick or anything. He’s b- he’s a busy dude. But you know, it just feels good to be here. My son lives here in Atlanta, and so I, I would love to be a, a drive away or a 90-minute flight instead of, like, a whole day of travel, you know? So there’s a lot of things, besides the taxes and all of those things. I don’t have a runway like a 30-year-old. I have a runway like a 55-year-old that’s been divorced a couple times, you know what I mean? So we gotta be using our brains here. So I was like, “I’m gonna just go down to Florida and I’m gonna look around.” Tampa checks a lot of boxes because there’s the big airport, it’s a city, it’s by the beach, and, like, that St. Petersburg area. I’m like, “Okay. Well, this could be a place where I could see myself.” And so I thought, “I’m gonna go down there. I’m gonna rent a car and just drive all over.” And as it ended up, somebody reached out from Instagram, and she lives there, and she was like, “I’ll show you around.” And I had, like, the best w- I had the best weekend with her. So it was like I made a really good friend while I was down there. But here’s what happened. I decided I was gonna go down Thursday night. So I was gonna be here for my coaching that I do. We have the Navigate group on Thursdays, and I n- I never miss it. Like, it is a strange, strange moment if I miss it. Um, maybe once a year I will miss. Like, I, I mean, I, this is, like, my favorite thing ever, so I never wanna not be there. So I, although I have coaches that are amazing, and they would be amazing, but I’m just like, “I wanna, I, I wanna be there.” So I’m like, “I’ll do the coaching, and then- pack up my stuff, and head to the airport. I’ll take a flight that night. I’ll land in Tampa. I’ll just get a hotel right near the airport. That’ll be easy-peasy, and then in the morning when it’s light out, I’ll begin my adventure, you know? The next day, Friday morning, was my birthday. It was my 55th birthday. And here’s the thing. I thought to myself, “You know, I wanna be by the ocean on my birthday. That sounds really fun. And, you know, why not have a little adventure?” So that Thursday morning when I was prepping for the Navigate group, I thought, “I need to go bring my cat to the kitty hotel,” right? Like, get Dean Martin situated. Then I can do my thing and head out. And when I was walking around the house, I was, you know, picking up stuff and playing with the cat and doing whatever I needed to do, and I was talking to my mother. Now, if you’re new here, my mother transitioned back when I was in high school, when I was 16. She died when I was … Transition is such a… She croaked. When I was 16 she died in a car accident, and so I’ve never… You know, I haven’t gotten a birthday present from her since I was 16. And I said out loud, “You know, I talk to you a lot, and I trust that you’re here.” But I don’t know. You know, I was kinda like in one of those, like, prove it kind of moods. So I was like, “I don’t know. I don’t know if you’re really here, but if you are, I would like a birthday present. Haven’t had a birthday present from you in a long time, and I would love a birthday present, and I would love if it was something really obvious.” Do you guys do that, too, where you’re like, “Make it a sign,” and then the sign comes, and then you’re like, “Make it a signier sign. I need it to be super signed.” So I was like, “I want a birthday present. I want it to be really obvious.” And I said out loud, “I want it to be really obvious, not like an Amazon gift card or something,” which is kind of a weird thing to say, ’cause I would happily accept an Amazon gift card. But I, you know, said it out loud, and I actually felt it when I said that. Like, it felt funny when I said it, and then I continued. I was busy, busy. I was a busy girl all day. And anyway, I get to the airport. I get settled into the Sky Club because I have a Delta corporate card. I’m about to tell you all of the things that I require to travel, but I’m also too cheap to pay for them, so I have like a million workarounds. So first of all, I got my flight for free using points. I buy a coach seat, but I am Platinum, so I always get upgraded. Why am I Platinum? It’s not because I travel all the time, but it’s because I use my Delta corporate card for everything, for all my business stuff, right? So we end up putting a lot through that, and it gets me to Platinum status, okay? The cool thing about Platinum is you get to choose, like, your present, you know what I mean? Like, you get to choose the thing that you get. And so I have chosen, and I think you have to choose for the year, and I have chosen that I would get upgraded. So I always buy a coach seat, and typically I’ll get upgraded at least to Comfort Plus. I’m a short woman, so it’s not like I need a ton of leg room, but I like … I, I, I feel like my thing is I like- space. Like I don’t like to be herded places, and I don’t wanna feel crowded or rushed. Like that really stresses me out. So I get to the airport, I go to the Sky Club, which I have access to because I have the corporate card, not ’cause I, I’m too cheap to pay for that. But I have a corporate card, and go to the Sky Club, I hang out. It’s time to board the plane, and I look and I’m still not upgraded. And I’m like, “This is really weird.” I mean, it’s a short flight, so like I can hang in coach, but I’m in the middle. And I’m always on the end. Like I, I, I know it’s only 90 minutes, but I always have to pee. Like I’m like, I g- I need to be on the end. I don’t wanna be like in the middle. Ugh. But I’m in the back of the plane. I’m like in seat 29 in the middle seat. But it’s 90 minutes. I’m like, “It’s fine.” I get on the plane. There I am, like, you know, with my shoulders in, I’m as small as I can be so that the people on either side are taking up so much room. And I’m thinking to myself like, “You know what? I hate this.” Like I just do. And it’s okay. I’ll survive, right? Like it’s, if this is the worst of my issues this weekend. But I hate it. And so then the s- airline, um, not the pilot, the flight attendant says, “You know, we’ve oversold this flight.” It was already like delayed. You know? It was like 10 minutes delayed or something. Like it was a busy and it was late, you know. And I could tell they’re tired, and they’re like, “We’ve oversold this flight, and we need somebody to get off the plane and get on a flight two hours later if somebody’s interested in doing that.” Can you ring your bell? You know? So I ring my bell. ‘Cause immediately I’m like, “I don’t even wanna be on this flight. Like, I, I would pay you to go to the next flight.” And they’re giving a $600 voucher, so I’m like, I mean, I travel enough, I have enough things planned, so I’m like, “Yeah, heck yeah, I’ll do that.” Ring my little bell, the flight attendant comes over. She says to me, like, “Do you have luggage?” I’m like, “It’s on the plane.” She’s like, “It’ll be there waiting for you.” I’m like, “That’s great. I trust, I trust.” So I get off the plane, and the people at the f- at the gate, like the f- attendants at the gate are like, “Oh, did you… Thank you for, you know, shifting and going to the later flight.” I mean, it boards in, like, an hour, so I’m like, I’ll just go back to the Sky Club, get a drink, and by the time it’s, I’m done my drink, it’ll be time to board. And nobody’s waiting for me. I’m just… I just got a hotel at the, at the airport. Do you know what I mean? So I’m like, this is no… Like, how nice for somebody else that they could get off the plane, and I am gonna get a $600 voucher. So she says, “Thank you.” I’m like, “Yep, no problem.” And then she’s like, “It won’t print.” And she keeps trying to print, print the voucher, print the voucher, and then she says to the woman next to her, “Do you know why this isn’t printing?” And she’s like, “Well, press this, you know, press that. Try it again. Can you refresh? Maybe if we…” Like, they’re, they’re, they’re going through it, you know? And like I said, it’s late. I can tell these people have had a day. Like, she’s just like, “I can’t get this to print.” So she calls, and she says, like, “It’s printing, but it’s not printing the voucher.” And she’s like, “Will you email it?” So then she looks at me, and she’s like, “Can you check your email?” I’m checking my email. I’m checking my junk. There’s nothing. She’s like, “Try to email it again. It’s not coming through.” She doesn’t have anything. They try it again. And finally she shoves a piece of paper in my hand, and was like, “Here, take this.” So I took the paper and went on my way. I got myself a drink, I sat down, and I looked down, and what did I have but a voucher for a $600 Amazon gift card. Now- Here’s the thing. Here’s the thing. What is actually happening? What’s actually happening? Now, you could hear this story and be like, “Well, that was a coincidence.” Like random, like really good timing, funny timing. Or I could tell you that there’s magic, magic all around us, and it is just what we choose to believe. Everything is what we choose to believe. And both of those things are true. It could be a coincidence, could be random. It is funny timing, and it does feel magical, and that is what I would like to believe. But here’s what else is true, is that there is part of our brain that you’ve heard of called the reticular activating system, the RAS, and its job is to filter, okay? So your brain is taking in like several million pieces of information every second. And when I say your brain, I mean, like, your nervous system. So, like, you’re seeing things and hearing things and feeling things and smelling things. Like, all this stuff is coming in all at once. And you can only consciously pr- like, process 126 of those pieces of information, so that means there’s a lot of information that’s just getting lost. It stays in the back of your mind. It stays in your brain. You just aren’t consciously aware of it. So there’s like a little mailman in there that is filtering stuff. It’s taking in all the mail and looking at it and throwing you the pieces that it thinks are important. It decides what gets through to your conscious awareness and what gets tossed out as, like, background noise. So the RAS filters for what you’re focused on. I remember when I bought my car. I have a little white SUV. It’s not rare. But I bought that car and I thought, “I’ve never seen this car before. Like, this is so unique and special,” I thought. I bought it, and now sometimes I go to the grocery store and I’ll come out and there’s like four of them in a row. Like, they’re everywhere. Everybody has them. I just wasn’t looking for them before. My RAS wasn’t set to notice those. So when I asked my mom for a sign, and I said, “Make it obvious,” and when I joked about an Amazon gift card, I set my RAS to look for it. And so when it showed up, I felt something. I noticed. Someone else might have glanced at the voucher and thought, “Oh, .” Y- you know, whatever. . But I was looking for magic, and so I saw it. I felt it as proof So here’s what I’ve been thinking about since that trip. When we are sitting in the middle of hard things, you know, a hard decision. I, I was going down there to look for a place that I was gonna move to live, and I’ll give you the update on that. It’s… There’s… I, I still have questions. But when we’re in the middle of this big, hard decision, it can feel really crushing to carry it all by ourselves. You know, I was feeling that, the weight of it, the fear that I’m gonna choose wrong or miss something, the exhaustion of trying to figure out every single piece of this all on our own. And, you know, I talk a lot when I talk online, and I talk about the Navigate method, and I talk about how important it is for women to make decisions for themselves, and I believe that. I believe nobody else should make the decision for you, ’cause this is how we learn to trust ourselves. But what if we didn’t have to totally do it all on our own? What if we could hand something over, like, like, like, one little thing, and let ourselves be guided? You know, let ourselves be cared for. I, uh, this weekend or that weekend, it was last weekend it was such a lesson in allowing myself to be cared for. You know, did, did my mother give me the $600 Amazon gift card? I think so, but I think she also gave me the friend that took care of me, that took care of everything. If you follow along on Instagram, you know I got food poisoning. She took care of me. She mothered me. And I needed that so bad. And so what if we could let ourselves be guided, let ourselves be cared for, let the universe meet us part way? I’m not saying let somebody else make the decision for you, but I’m saying the decision can be easier when you’re not white-knuckling your way through it all by yourself. So here’s where I think the brain part of this gets really interesting. You know, when we grip, you know, when we’re in control mode, when we’re trying to force an outcome or manage every single variable, our nervous system is really in protection mode. And then what does my RAS do, is it starts filtering for threats, right? It starts looking for like, “Oh my God, she thinks something’s gonna go wrong. What could go wrong? What do I need to control? What am I missing? What am I not seeing? Show her the fear. Show her the unsteadiness.” Right? And when your brain is doing that, you literally can’t see the help that’s available. You can’t notice the signs. You can’t receive any new ideas or, you know, the other options and, you know, doors that you wanna be open seem closed, because your brain isn’t scanning for that stuff. Your brain is scanning for danger. It’s scanning for what could go wrong. It’s scanning for all the times you’re walking on eggshells or afraid you’re gonna make a wrong decision. But when you physically let go, when you open your hands, when you open your hands and you ask for help out loud, something shifts. I do think there’s something magical about speaking it out loud. I think when I was talking to my mom and I was doing it out loud, I could… There was something. Have you ever had that feeling where you’re like, “I feel something moving in me,” you know? And our nervous system reads that as safety, right? It stops filtering for threat- And it starts filtering for possibility when I’m speaking out loud, when I’m calm, when my hands are open. You start noticing things you couldn’t notice before, not ’cause they weren’t there, but just ’cause your brain wasn’t looking for them. Okay, so there’s another piece to this. Your brain is also a, a pattern-matching machine. Like, it’s constantly scanning for patterns. It’s constantly trying to prot- te- uh, I wanna say protect, but no, predict. I w- it’s constantly trying to predict what’s going to happen based on what’s happened before. And when you’re stuck in hard decisions, when you’re stuck in looping on the same thoughts over and over again, you’re reinforcing those same neural pathways. You’re telling your brain basically, “This is the pattern. This is what we do here.” And your brain just keeps running that pattern over and over and over again. This is how come, like, y- y- you know, your partner may stomp around the house, and you go, “Oh, my God. I know what’s gonna happen ’cause I know what happened before,” right? I, I can feel it. I know something’s gonna go sideways. And so you start walking on eggshells. You start being… You’re hypervigilant. You’re listening for w- whatever sound, rustle in the grass you need to be aware of so that you can protect yourself, right? But when you let go, when you put something down, you know, it, your brain can, can shift to something new. It’s not like you’re doing something wrong by listening to those patterns, it’s just that your brain is doing what it’s designed to do, and it’s conserving energy, right? So it’s running a program that it already knows. But when you put it down, then you create space, and in that space, you can form all new patterns. You know, new thoughts can come to you, new ideas can come through, new possibilities can show up that weren’t available when you were gripping really hard. And this is why people say things like, um, like, “I stopped trying so hard, and then it just happened. Like, I don’t know, it just happened. As soon as I let go of needing it to work out, like, it just became obvious.” And it’s not magic. Well, it’s a little magic, but it’s neuroscience. You created space, and your brain had room to find a new pattern. Okay, so here’s how we’re gonna put this into practice. I’m gonna give you something you can try this week. I call it the put it down, put it down practice, and it is designed to shift you from really gripping to having your hands open and receiving. So it’s, it moves you from that, like, control mode to open mole- mode, and then y- you, you kinda stop… You stop scanning for threat, and then you start essentially scanning for what’s available. So here’s how it works. Step one is you’re gonna name what you’re holding. So say it out loud if you can, like the decision, the outcome, the how. So I’m holding the question of whether to stay or go. I’m holding the fear that I’m gonna choose wrong. I’m holding the need to figure out how this is all gonna work before I take my first step. So just name it, whatever it is. I’m holding the overwhelm of trying to find where to live. So step two is you physically put your hands out. There is a, a, a loop between your body and your brain, and I’m gonna use my body to send alerts to my brain. I know it sounds kinda simple, but your, your body and your brain are connected. So when you open your hands, you’re signaling to your nervous system that you’re receiving. You’re not grasping, you’re available, right? Not defending anything. It’s, it’s how your nervous system reads safety, okay? So you’re gonna physically put your hands out, palms up. And then step three is you’re gonna ask out loud, “What’s the one thing I can hand over right now?” Not, “What should I do?” Or not, like, “How do I fix this?” But, “What is one thing I can hand over?” And you’re gonna ask it to the universe, or to God, or, uh, to your dead mom. Like whatever it is, whatever it is that works for you. And ask it to the part of you that already knows. It doesn’t matter who you’re asking, really. It just matters that you’re asking. And then step four is that you’re just gonna wait. Don’t answer it yourself. Don’t, like, fill that silence with your own voice. Just wait and let the answer come to you. This is such a skill to learn to just, like, wait until you feel something. So then the fifth step, I guess we’d be on step five, right? Notice what shows up in the next 24 hours, 48 hours. It might be a thought you didn’t have before, a conversation that feels different than it would have a couple days ago. You know, maybe an opportunity that opens up, you weren’t even looking for one. Maybe it’s a $600 Amazon gift card when you specifically said not that. The point is, you’re not looking for something, like, specific. You’re not looking for a specific answer. You’re looking for movement. You’re looking for the thing that you couldn’t see when you were holding on so tight, you know? I did ask my dad, I said, “What are you sending me?” ‘Cause my mom gave me a $600 gift card. “What are you gonna get me?” It was probably a joint gift, I think. So this is what happens when you’re sitting in the middle of a, a big decision. You know, trying to move to the beach, trying to make a decision about your marriage, and you’re trying to logic your way through it all alone. You keep pushing. You keep thinking. You keep trying to see around corners and, you know, predict outcomes, manage things that you can’t actually control, and then your brain keeps running the same loop, right? It keeps asking the same questions and having the same fears and patterns. So what if, what if you didn’t have to carry all that by yourself? What if you could just hand one thing over and let yourself be supported, let yourself be guided, let yourself receive help instead of white-knuckling your way through it alone? I, I don’t think the decision gets made for us, but the decision gets clearer, I think, when you stop gripping so hard. So pick something this week. Maybe it’s something easy, something that doesn’t have a lot of emotional charge to it, and do the put it down practice. Do- just try it once. See what happens. Name the thing you’re holding, open your hands, ask the question out loud, wait, and then pay attention. Because magic is all around us. It’s, it’s just what we choose to believe, and if your brain is designed to find what you’re looking for, ask it to look for help. Ask it to look for signs. Look for the thing that you couldn’t see when you were in protection mode. And I think when you can do that, that is how you live a big life. If you want help on this journey, we’ve got some spots available on the calendar this week. Um, if you are interested in the Navigate Method, or if you’re not quite there yet, you’re like, “I don’t, I don’t wanna go all in on all that,” I have a process on my website called The Bridge, and it is a truth map that will guide you to the next right thing. And then maybe at that point you’ll be ready to do some of the deeper work inside the Navigate Method. But we are here when you’re ready. Be open to it and allow us to help pick up what you’re carrying. I love you guys so much. I’ll see you next week Thanks for joining me on The Art of Living Big. I hope today’s episode sparked something within you, maybe pushed you to dream a little bit bigger and live a little larger. Don’t forget to subscribe. Leave us a review and share this podcast with someone you know who might need a little inspiration today. You can find me over on Instagram at Betsy Pay and on my YouTube channel. Remember, the world is vast. Your potential is endless, and your life, it’s yours to shape. Until next time, keep reaching, keep exploring, and keep living big.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification.“Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

Στο νέο επεισόδιο της σειράς «Η επιστήμη και οι επιστήμονες» της Athens Voice, ο Γιώργος Παυλάκης μιλά για τη διαδρομή του στην έρευνα, τη φύση της επιστήμης και τις μεγάλες προκλήσεις της σύγχρονης ιατρικής. Ξεκινώντας από τα παιδικά του χρόνια, περιγράφει πώς επηρεάστηκε από το όνειρο του πατέρα του να γίνει γιατρός και πώς ήδη από το δημοτικό είχε στραφεί προς τη βιοχημεία και την επιστημονική αναζήτηση. Τονίζει ότι η επιστήμη, παρά τη γοητεία της, είναι κυρίως μια διαρκής διαδικασία αποτυχιών, όπου ο ερευνητής πρέπει να μάθει να «πέφτει και να ξανασηκώνεται». Σύμφωνα με τον ίδιο, το 99% των πειραμάτων αποτυγχάνει, αλλά κάθε αποτυχία μπορεί να οδηγήσει σε νέα γνώση. Ο Παυλάκης εξηγεί πως η έρευνα απαιτεί ακραία εξειδίκευση, γεγονός που συχνά περιορίζει τη γενικότερη εικόνα, ενώ παράλληλα αναφέρεται στη χαρά της ανακάλυψης, περιγράφοντας τη στιγμή που κατάλαβε ότι ένα «αποτυχημένο» πείραμα αποκάλυπτε έναν νέο μηχανισμό ανοσοθεραπείας για τον καρκίνο. Εστιάζει ιδιαίτερα στις εξελίξεις στη θεραπεία του καρκίνου, επισημαίνοντας ότι πολλές μορφές του πλέον είτε ιάσιμες είτε μετατρέπονται σε χρόνιες παθήσεις. Ξεχωρίζει τη σημασία των νέων θεραπειών για τον καρκίνο του παγκρέατος, που βασίζονται στη στόχευση του γονιδίου RAS, αποτέλεσμα δεκαετιών ερευνών. Σημαντικό μέρος της συζήτησης αφιερώνεται στην ανοσοθεραπεία, την οποία παρουσιάζει ως μια επανάσταση σε σχέση με τη χημειοθεραπεία, καθώς αξιοποιεί το ίδιο το ανοσοποιητικό σύστημα για την καταπολέμηση του καρκίνου. Περιγράφει επίσης τη συμβολή της τεχνολογίας mRNA, τόσο στα εμβόλια κατά της Covid-19 όσο και στις μελλοντικές θεραπείες για τον καρκίνο και το AIDS. Αναφερόμενος στην πανδημία, υπογραμμίζει ότι οι Κινέζοι επιστήμονες αντέδρασαν γρήγορα δημοσιεύοντας το γενετικό υλικό του κορωνοϊού, γεγονός που επέτρεψε την ταχεία ανάπτυξη διαγνωστικών εργαλείων και εμβολίων. Παράλληλα, εκφράζει ανησυχία για το μέλλον της ανθρωπότητας απέναντι στις νέες τεχνολογίες και την τεχνητή νοημοσύνη, σημειώνοντας ότι η τεχνολογική πρόοδος δεν συνοδεύεται πάντα από ανάλογη ηθική πρόοδο. Κλείνοντας, ο Παυλάκης τονίζει ότι κάθε επιστήμονας προσπαθεί να προσθέσει «ένα μικρό βοτσαλάκι» στο οικοδόμημα της γνώσης, βασιζόμενος πάντα στο έργο των προηγούμενων γενεών και αφήνοντας παρακαταθήκη για τις επόμενες. Με την υποστήριξη των Σίμου και Ζέτας Παληού Συντελεστές Sound design, ηχοληψία: Κάκια Γκουδίνα Η ηχογράφηση έγινε στο Athens Voice Studio

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Alhamdulillāhi Rabbil ‘Alameen. Wa salātu wa salāmu ‘alā ashrafil anbiyā’ wal mursaleen, Muḥammadur Rasūlullāh ﷺ, wa ‘alā ālihi wa sahbihi ﷺ. Tasliman kathīran kathīrān. Qamun badu. My brothers and sisters, we are entering, insha’allah, from tomorrow the 1st of Dhul Hijjah. So the first nine days of Dhul Hijjah—ten days… Continue reading What did I earn today

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Alhamdulillāhi Rabbil ‘Alameen. Wa salātu wa salāmum ‘alā ash-sharafi al-anbiyā’ wal-mursalīn, Muḥammadir Rasūlullāh ﷺ, wa ‘alā ālihi wa sahbihi wa sallam. Tasleeman kathīran kathīran. Fammabadu, my brothers and sisters. Alhamdulillah, we are in the ten best days of the year, which are the first ten days of Dhul-Khaidah, Dhul-Hijjah. And… Continue reading Udhiya – Qurbani

Reality INspyrd | The Law of Observation, Your RAS & Co-Creating Your Reality Hey, firefly. This one's for you. ✨ In this episode Ashley goes deep into the Law of Observation and the silver thread connecting quantum physics, synchronicity, and your Reticular Activating System (RAS) — the network of neurons in your brain stem that filters what you consciously see and experience every single day. Whatever you are observing, expecting, and collecting evidence for... your reality keeps delivering. The question is — what are you tuned into? In This Episode We Cover: What the Reticular Activating System (RAS) is and how it shapes your reality Whether synchronicities were always there — or if you're co-creating them How limiting beliefs get wired in through your upbringing, environment, and lived experiences The observer effect — quantum physics, the tree in the forest, and what it means for your life How to consciously reprogram your RAS through hypnosis, meditation, breathwork, prayer, and affirmation Karma, fate, and what it means to learn through the hard stuff Being the alchemist of your own life Why getting present every day is the most radical act of self-reclamation Ashley's personal tools and an open invitation to go deeper Referenced In This Episode: Dr. Joe Dispenza Gregg Braden The Matrix — the observer effect + quantum reality The Reticular Activating System (RAS) The observer effect in quantum physics Try This: Pick something simple — a blue butterfly, an owl, an old $5 bill. Set the intention to see it. Watch what your RAS does. Then ask yourself — what else are you open to? Work With Ashley: If you want support through breathwork, hypnosis, meditation, or movement — Ashley's got you. Reach out via Instagram or the website below. If this episode resonates with you, please subscribe, leave a review, and share it with someone who needs it

Hokejový osud občas píše scenáre, ktoré by nevymyslel ani ten najlepší hollywoodsky dramaturg. Ešte pred pár rokmi by mu možno reprezentačný dres nepredpovedali, no dnes je pevnou súčasťou slovenskej defenzívy na prebiehajúcich MS v hokeji 2026. Obranca HK Dukla Michalovce Jakub Meliško prijal pozvanie do najnovšej epizódy hokejového videopodcastu suSPEAK na ŠPORT.sk.V uvoľnenom a mimoriadne úprimnom rozhovore s moderátormi Marekom Marušiakom a Rasťom Konečným odhalil nielen zákulisie svojho neskorého reprezentačného debutu, ale aj úsmevné momenty zo svojej bohatej a poriadne spletitej kariéry.Málokto debutuje v národnom A-tíme na prahu tridsiatky. Keď Jakubovi Meliškovi vo veku 29 rokov zazvonil 1. apríla telefón a na druhej strane sa ozval reprezentačný tréner Vladimír Országh, obrancovou prvou reakciou bola logická a úsmevná nedôvera.„Tak som mu hneď povedal, že je prvý apríl, tak sa začal smiať a povedal, že s takými vecami sa nesranduje,“ spomína na moment, ktorý mu definitívne zmenil kariéru.Oslavy tohto životného míľnika v michalovskej šatni mali tiež svoj špecifický náboj, keďže mu starší spoluhráči na čele s Milanom Kytnárom okamžite prízvukovali, aby si z nominácie nerobil žarty, no nakoniec sa z úspechu tešila celá kabína.Okrem čerstvých reprezentačných zážitkov sa poslucháči dozvedia aj to, prečo herný prejav Jakuba Meliška často pripomína skôr ofenzívne ladeného útočníka než klasického defenzívneho deštruktora. Máloktorý fanúšik totiž tuší, že Jakub Meliško si vo svojej kariére prešiel aj ofenzívnymi fázami a niektorí tréneri mali s ním iné zámery.Vo videopodcaste so smiechom uviedol veci na pravú mieru, keď spomínal na snahy trénerov o zmenu jeho postu. „Ja som bol obranca, ktorého chceli prerobiť na útočníka. Chvalabohu, to nespravil nikto,“ dodal pohotovo, čím len potvrdil, že moderný hokej si vyžaduje presne takých kreatívnych bekov, akým sa napokon stal.Cesta do stabilného michalovského kádra a následne do reprezentácie však nebola zďaleka priamočiara. Odchovanec žiarskeho hokeja okúsil vo svojej kariére aj legionársky chlebíček. V rozhovore detailne a pútavo popisuje svoju francúzsku anabázu v Bordeaux, kde sa vybral hľadať väčší priestor na ľade.Rovnako zaujímavé je aj jeho spomínanie na mládežnícke pôsobenie v českom Chomutove. Práve u našich západných susedov ho čakala výzva, pri ktorej sa zapotil možno viac ako na ľade – maturita z českého jazyka. Poslucháči sa tak pobavia na historke, ako sa slovenský hokejista popasoval s písomnou prácou z češtiny, pri ktorej sa neváhal inšpirovať kultovým americkým seriálom.Ak chcete spoznať defenzívnu oporu Slovenska z úplne inej stránky, vypočujte si najnovšiu epizódu videopodcastu suSPEAK. Dozviete sa, aká panovala atmosféra v kabíne Michaloviec počas turbulentnej sezóny, ako si Jakub Meliško užíva letné cyklistické výjazdy s Marekom Minárikom na Zemplínskej Šírave a prečo ho kedysi v kabíne nútili postaviť sa do bránky. Tento rozhovor je presne taký, aký je Jakub Meliško na ľade – plný prekvapení, nečakaných útočných výpadov a zdravého nadhľadu.

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Alḥamdulilāhi Rabbil ‘Alāmīn. Wa salātu wa salāmu ‘alā ash-sharafi al-‘Ambiyā’i wal-Mursalayn, Muḥammadur Rasūlullāh sallallāhu ‘alayhi wa ‘alā ālihi wa sahbihi ṣallam. Tasliman kathīran kathīran. Umma ba’du. My brothers and sisters, alḥamdulillah. We have been talking about the issue of istighfār and tawbah. And we ask Allāh subḥānahu wa ta’ālā to… Continue reading What is Tawba – #6

What if the reason your affirmations are not working has nothing to do with how hard you are trying, and everything to do with how your brain is wired? In this birthday special solo episode, I am pulling a teaching straight from inside the Creative Frequency to introduce you to one of the most powerful mindset tools I have ever used: askfirmations. These are not affirmations. They are curiosity-driven questions that hijack your Reticular Activating System and send your brain on a search for evidence, opportunities, and possibilities it was literally filtering out before.I am breaking down the real neuroscience behind why curiosity works better than forced belief, including how it activates dopamine, lowers nervous system resistance, and bypasses the identity blocks that keep you stuck. I also walk you through the full askfirmation practice so you can start using it today. This one is a gift, literally. It is my birthday, I am turning 55, and I am giving you access to the kind of teaching I usually only share inside my paid programs. Do not skip the show notes. There is a birthday gift waiting for you there too.In this episode, you'll learn:00:27 -- Austin, Birthday week, and what is coming this summer01:06 -- Why so many people are in a hard season right now and what curiosity has to do with it02:19 -- What the Creative Frequency is and why I pulled this teaching for the show04:59 -- What askfirmations are and why they work where affirmations fall short07:25 -- The neuroscience: RAS, identity, nervous system, and how curiosity rewires all of it13:39 -- How curiosity activates dopamine and shifts you from desperation to energized pursuit16:49 -- How to practice curiosity daily and the stillness ritual that makes it land19:19 -- Your askfirmation exercise: how to write, record, and use your list every single day20:48 -- Birthday gift announcement: free visibility activations from The BreakthroughHere are the resources mentioned in the show:Birthday Gift - Free Visibility ActivationsThe Creative FrequencyThe Wealthy Creative SocietyAre you enjoying the podcast? We'd be so grateful if you gave us a rating and review! Your 5 star ratings help us reach more businesses like yours and allows us to continue to deliver valuable content every single week. Click here to review the show on Apple podcast or your favorite platformSelect “Ratings and Reviews” and “Write a Review”Share your favorite insights and inspirationsIf you haven't done so yet, make sure that you subscribe to the show wherever you listen to podcasts and on Apple Podcast for special bonus content you won't get elsewhere.xo, Tracy MatthewsFollow on Social:Follow @Flourish_Thrive on InstagramFollow @iamtracymatthews  InstagramFollow Flourish & Thrive Facebook

If you've been doing the affirmations, the scripting, the law of assumption work, and still not seeing results, it's not because the techniques aren't working. It's because your brain is running a filter that was installed before you ever had a choice. Your brain isn't showing you reality. It's showing you what it's been trained to perceive. And if your identity says money is stress, your RAS will scan your entire reality to prove that true.This isn't about mindset. It's neurological. The version of you making financial decisions right now might still be the child who learned that money meant fear, silence, or unpredictability. Until you identify that identity and upgrade it, it doesn't matter how much opportunity shows up. Your brain won't register it as safe.Episode Takeaways:Understand why your brain filters out money opportunities it doesn't recognize as safeIdentify the money story your nervous system installed in childhood and is still running todayMeet your future financial regulated self, the version of you that receives money without stress or survival energyThe woman who walks away from this stops blaming strategy and starts looking at identity. She stops asking "how do I get more money" and starts asking "who do I have to become to receive it." That shift is where everything changes. If this episode resonated, your first month inside the Manifesting Miracles Academy is completely free — link below.✨ MANIFESTING MIRACLES ACADEMY  ✨ Your first month is completely free.Join now: https://manifestingmiracles.thinkific.com/pages/memberships 

It's In The News, where we bring you the top diabetes stories and headlines happening now. Top stories this week: Dexcom shares details of its next generation CGM, T1D and GLP-1 studies, weight loss management on GLP-1 medications updates, all-in-one CGM and pump, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: XX Dexcom announces some features of it's next generation CGM – the G8. We've been talking about this with CEO Jake Leach for a while now – it will be a 50% smaller with what they're calling advanced sensing capabilities. According to Leach, G8 will adapt to the physiologic variability of each user. It has additional technology built in, based on a new silicon chip design and algorithm. 15 day wear is now the baseline for all Dexcom sensors moving forward. At launch the G8 will only measure glucose but the plan is for a multi-analyte version to follow. That would measure ketones and potassium. Ketones we know – but potassium is very important for people with kidney and possible for people taking some diabetes meds. It's an interesting space to watch.. btw, analyte is just a medical word for the specific thing you're measuring – the target of the test you're running. we're going to hear that word a lot I think..   Looks like an FDA submission for the G8 next year.. with an outside the US launch the following year. https://www.drugdeliverybusiness.com/dexcom-unveils-next-gen-g8-cgm/ XX Glucotrack has submitted its implantable continuous blood glucose monitor (CBGM) for FDA IDE, that's investigational device exemption and would enable the company to initiate a U.S. clinical study for the fully implantable technology. Rutherford, New Jersey-based Glucotrack's device features no on-body external component. The company aims to offer it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. The implant goes five centimeters within the subclavian vein. Glucotrack's active implantable device has a small battery and some electronics that go just under the skin in the pectoral region. The location of the implant is not in a major vessel, but the implant can measure real-time glucose levels as pulsatile blood flows over the tip of the sensor. https://www.drugdeliverybusiness.com/glucotrack-submits-long-term-implantable-cbgm-fda-ide/ XX PharmaSens today announced the publication of data from the first clinical study evaluating its all-in-one insulin patch pump offering. The all-in-one pump pairs the Niaa Essential insulin patch pump with the SynerG continuous glucose monitor (CGM) sensor developed by Pacific Diabetes Technologies. However, this system would be one device that features both the pump and CGM technology.   PharmaSens and SiBionics also have a collaboration aimed at developing the all-in-one solution. They are jointly developing the next-generation Niia insulin patch pump with a SiBionics CGM. PharmaSens expects a second feasibility study in the second quarter to evaluate the next-generation pump with SiBionics' CGM.   PharmaSens says the clinical feasibility study of Niia demonstrated for the first time ever that the combined offering is, in fact, feasible. It believes its device addresses the need for alternatives to multi-device diabetes management. systems.   Aggregated MARD for the investigational device came in at 11.6%. A MARD target of less than 10% is considered ideal for CGM devices, but PharmaSens said that, in the context of the early feasibility study, the results were encouraging and provide evidence supporting the development of an all-in-one system. https://www.drugdeliverybusiness.com/pharmasens-efs-insulin-patch-pump-cgm/ XX   XX ViCentra launches the newest version of the Kaleido pump system in Europe. This is that small colorful pump, with Diabeloops algorithm and the Dexcom G7. It'll be in Germany and the Netherlands later this summer. https://hellokaleido.com/vicentra-announces-commercial-launch-of-new-smartphone-controlled-kaleido-automated-insulin-delivery-patch-pump-system/--   XX Diabeloop just got CE Mark approval for DBLG2 integrations – it's latest AID platform the company has kicked off the gradual European launch of the technology. It currently offers DBLG2 as a smartphone application on Android, with iOS integration coming soon. As you just heard, it's integrated with kaleido and the company says it plans to make additional configuration for DBLG2 with alternative pumps "available soon." Running on a user's smartphone, DBLG2 works as a self-learning algorithm. It continuously analyzes glucose data, calculates insulin needs in real time and automatically adjusts delivery. https://www.drugdeliverybusiness.com/diabeloop-fda-next-gen-algorithm-g7/   XX Among adults with type 1 diabetes (T1D), the initiation of GLP-1-based therapy was associated with a lower risk for all-cause death, several cardiovascular outcomes, all-cause hospitalisations, and hypoglycaemia, without a higher risk for diabetic ketoacidosis.   METHODOLOGY: Researchers in Greece conducted a retrospective cohort study utilising real-world data from a global health research network to evaluate the association between GLP-1-based therapy and cardiovascular and renal outcomes in adults with T1D. A total of 4088 patients receiving GLP-1-based therapies (median age, 43 years; 34.3% men) were propensity score matched with an equal number of patients not receiving the treatment. The risk for hypoglycaemia was lower with GLP-1-based therapy (hazard ratio, 0.72; P = .021); however, the risk for diabetic ketoacidosis did not differ significantly between the two groups. https://www.medscape.com/viewarticle/glp-1-drugs-tied-cardiovascular-benefits-t1d-2026a1000fbx   XX Eli Lilly and Company (NYSE: LLY) today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. The findings from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, were presented at the 33rd European Congress on Obesity (ECO) and published in The Lancet and Nature Medicine, respectively.   "Weight regain remains one of the biggest challenges in obesity care, and is often the result of treatment interruptions that cause biology to work against patients, undoing the progress they've made," said Louis J. Aronne, M.D., FACP, DABOM, founder and Chair Emeritus of the American Board of Obesity Medicine, former president of The Obesity Society, Fellow of the American College of Physicians, world-renowned obesity specialist and Lilly consultant. "These medicines can be used for long-term maintenance today, and results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN provide additional evidence of their potential when switching from higher doses of injectable incretin therapy." https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-and-lower-dose-zepbound-helped-people-maintain XX Scientists in Sweden have developed a more reliable way to create insulin-producing cells from human stem cells. These lab-grown cells not only respond strongly to glucose but were also able to restore blood sugar control when transplanted into diabetic mice. When transplanted into diabetic mice, the cells gradually restored the animals' ability to regulate blood sugar. Long way to go, as we say with most of these mice studies. https://www.sciencedaily.com/releases/2026/05/260505234620.htm XX Interesting look at how the body controls sugar storage – apparently this finding challenges long-standing biology concepts and could open new directions for disease treatment. Published in Nature, the study describes a potential method for directly reducing glycogen, the stored form of sugar in the body. These scientists discovered that glycogen can be directly regulated by ubiquitin, a protein best known for marking damaged proteins for recycling or removal. The study is the first to show that ubiquitin can regulate glycogen in humans, overturning more than 50 years of scientific understanding. Excess glycogen is also associated with more common health problems, including diabetes, obesity, liver disease, and heart disease.       https://scitechdaily.com/scientists-just-rewrote-biology-hidden-mechanism-could-transform-diabetes-treatment/ XX A new Oklahoma law will give parents the option to have their children screened for Type 1 Diabetes.   The measure passed with overwhelming bipartisan support in the Legislature and takes effect Nov 1. Oklahoma consistently ranks among the states with the highest rates of diabetes and diabetes-related deaths. The law gives parents access to antibody testing that can detect risk years before symptoms develop, helping families take preventive action and avoid emergency room visits. https://journalrecord.com/2026/05/11/oklahoma-law-expands-access-type-1-diabetes-screening/ XX More to come including a new study trying to figure out why some people are more likely to develop diabetes, a look at cannabis and preventing metabolic disorders, and XX   A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. "This study is the tip of the iceberg," said Dr. Evans-Molina. "We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data."   https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk XX XX XX Research published recently in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.   "This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.   Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.   What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Approved to treat type 2 diabetes in 2005 and weight management in 2021. Impacts on breast cancer survival and recurrence are still unclear. Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.   The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.   GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.   "Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings," said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.   What's next? Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.   "Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making," Fuemmeler said. https://www.oncology-central.com/could-glp-1-receptor-agonists-improve-outcomes-for-breast-cancer-patients-with-obesity-or-with-type-2-diabetes/ XX Researchers at UC Riverside gave cannabis to obese mice and found that not only did the rodents lose weight, but when given a concentrated cannabis oil, the mice also saw striking benefits in their metabolic function. DiPatrizio said his team studied the issue to better understand why cannabis users show significant reductions in weight and risk for diabetes compared with nonusers. "We would think that chronic cannabis users would be eating more and weigh more, but it's just the opposite," DiPatrizio said. Scientists are increasingly examining the possibility that cannabis compounds could fight obesity or metabolic disorders like diabetes. Cannabinoids interact with the body's endocannabinoid system, which partially controls nearly every aspect of our physiology, including metabolism and appetite. That creates the possibility that targeting this widespread system could unlock new therapies for these conditions. https://www.sfgate.com/cannabis/article/cannabis-weight-loss-california-study-22255328.php XX A new campaign launched by diaTribe and Genentech aims to empower and educate people about diabetes-related eye disease. Here's what you can do today to protect your eye health. To help address these barriers, diaTribe and Genentech partnered to launch All Eyes on DME, a new campaign that aims to spread awareness and educate people at-risk for or living with diabetes-related eye conditions like DME. Also partnering in the campaign is actor and comedian Damon Wayans, who wanted to share his journey (and, of course, a joke or two) with type 2 diabetes to open up the conversation about what is often a stigmatized or less talked about topic: eye health and diabetes.   One of these important conversations happened recently at the All Eyes on DME launch in New York City, where Wayans joined a panel of experts, advocates, and people living with DME to talk about diabetes-related eye disease and how to help prevent it. https://www.alleyesondme.com/dme-in-the-spotlight.html https://diatribe.org/diabetes-complications/all-eyes-dme-new-campaign-spotlights-eye-health-and-diabetes

This episode of the PeerDirect Medical News Podcast explores promising new data on the oral pan-RAS inhibitor daraxonrasib in KRAS-mutated pancreatic cancer, a randomized stroke trial evaluating adjunctive tirofiban after tenecteplase, and AI-driven breast cancer risk prediction models that may outperform breast density alone. Together, these studies highlight emerging advances in targeted oncology, acute stroke management, and precision screening technologies that could influence future clinical practice.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Alḥamdulilāhi Rabbil ‘Alāmīn. Wa salātu wa salāmu ‘alā ashrafil anbiyā’ wal mursalīn, Muḥammadir Rasūlullāh ﷺ, wa ‘alā ālihi wa sahbihī wa sallam. Tasliman kathīran kathīra khamma ba’du. My brothers and sisters, we are talking about perhaps the most important aspect of life: turning towards Allāh subḥānahū wa ta’ālā through istighfār… Continue reading What is Tawba – #3

On today's episode, we sit down with Denise Mickelsen from the Colorado Restaurant Association and Chef Ras Casiano of Lucina & Xiquita Restaurants to talk about the upcoming Drink Red Wear Red Fundraiser. A litany of restaurants will be participating, the community will be showing out & everyone is getting dolled up in their red flare! Great eats, great people... but starting with a great episode. We talk about the fundraiser, the new menu at Chef Ras's restaurant and then dive into some of their favorite places to hit up around town. If this episode piques your interest and you're looking to join the festivites on May 28th, use promo code STONED at check out when purchasing your tickets. I guarantee you'll have a big ol time! Become a supporter of this podcast: https://www.spreaker.com/podcast/stoned-appetit--3077842/support.

Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm. Al-ḥamdu lillāhi Rabbil-‘Ālamīn, wa-salātu was-salām ‘ala ashrafil-anbiyā’ wal-mursalīn Muḥammadir-Rasūlullāh ﷺ, wa ‘ala ālihi wa sahbihi wa sallam. Tasliman kathīran kathīra. My brothers and sisters, Alhamdulillah. We are on the fourth of the four truths that we have been talking about for the last few days. The first one is: Time… Continue reading 4 Truths – #7

If you've used music in therapy sessions and found it helpful you're going to love this one!  In this episode, host Erin Gallardo, PT, DPT, NCS interviews Brian Harris, MA, MT-BC, NMT/F, FACRM, a board-certified music therapist and founder of MedRhythms, about how music, neuroscience, and technology are being combined to transform neurorehabilitation. Brian shares the powerful clinical experiences that led him from traditional music therapy into developing neurologic music therapy programs at Spaulding Rehab Hospital, where rhythmic auditory stimulation (RAS) produced remarkable gains in gait and function for people with stroke and brain injury. To scale access beyond what one clinician can provide and take this evidence-based intervention into the home, he founded MedRhythms. They created prescription digital therapeutics that use wearable gait sensors, bone-conduction headphones, and "clinical thinking" algorithms to deliver personalized, music-based gait training at home for people with chronic stroke and Parkinson's disease. Now FDA-listed and supported by Medicare reimbursement, MedRhythms' products marry evidence-based neurorehab with user-friendly design, familiar music via a partnership with Universal Music Group, and ongoing clinical research to expand into additional neurologic conditions—bringing high-quality music-based rehab to more people who need it. MedRhythms www.medrhythms.com www.intandemrx.com www.movive.com https://www.facebook.com/MedRhythms https://www.linkedin.com/company/medrhythms

Auto-generated transcript: Bismillāh ar-Raḥmān ar-Raḥīm, Alhamdulillāhi Rabbil ‘Alāmīn, wa salātu wa salāmu ‘alā ashrafil anbiyā’ wal mursalīn, Muḥammadur Rasūlullāh ﷺ, tasliman kāseran kāseran. My brothers and sisters, we are looking at the four truths: the four truths that are true in life and which are important for us to keep in mind in order to… Continue reading 4 Truths – #6

Big Sal did not sleep last night. He was up until two in the morning reading draft grades, pacing the living room in his socks, and now he has something to say about it. Sports Illustrated gave the Green Bay Packers a D for their 2026 draft class, and Sal is here to burn that grade to the ground — pick by pick, stat by stat, slippers and all. Sal makes the case for Brandon Cisse as a Day 2 steal: a twenty-year-old corner who ran a 4.41 and allowed just eighteen catches in coverage at South Carolina — and why calling him "raw" misses the entire point of developmental drafting The picks SI barely mentioned: Chris McClellan's eleven-inch hands and scheme-perfect fit, Dani Dennis-Sutton's 9.96 RAS and fourth-round robbery, Jager Burton's zero sacks allowed and 4.94 forty at 312 pounds Why drafting Trey Smack is not a punchline — it is a direct response to Brandon McManus leaving seven points on the field in a four-point playoff loss Big Sal said what he said. Now it's your turn — subscribe, leave a five-star review, and tell the guy at the gas station who thinks the Bears had a better draft. #Packers #GreenBay #NFLDraft #PackNation #PackersDraft #LetMeTellYouSomething #BigSal #NFL #DraftGrades #PackDaddy This episode is brought to you by PrizePicks! Use code PACKDADDY to get started with America's #1 fantasy sports app. https://prizepicks.onelink.me/LME0/PACKDADDY To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast Help keep the show growing and check out everything I'm building across the Packers and NFL world: Support: Patreon: www.patreon.com/pack_daddy Venmo: @Packernetpodcast CashApp: $packpod Website: https://nfldraftgrades.com/ My Board: https://nfldraftgrades.com/board/83a18c42-7a0b-4590-8d1b-453e49840d02